CHA Biotech: Hospitals Generate Revenue, While New Drugs and CDMO Drive Growth—Its “Vertically Integrated Bio Business” Draws Attention

[Financial News] An analysis has found that CHA Biotech, a KOSDAQ-listed affiliate of CHA Bio Group, is building a business structure that connects stable revenue secured from global hospitals with cell therapy drugs and cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) operations. Unlike typical biotech companies whose performance depends on new drug development results, its vertical integration—from hospitals through clinical trials and production—is seen as a differentiating factor.
On the 7th, Lee Ho-jin, a researcher at Stunning Value Research, described CHA Biotech as “a bio platform that extends from hospitals to new drug development,” without issuing an investment rating or target price.
CHA Biotech operates a global healthcare network that includes CHA Hollywood Presbyterian Medical Center in Los Angeles, U.S., City Fertility in Australia, and Singapore Medical Group (SMG). Its consolidated revenue in the first half of this year rose 7.1% year on year to 646.1 billion won. Healthcare services alone generated 382.7 billion won, accounting for 59.2% of the total.
Regulatory easing is expected to serve as a turning point for the cell therapy business. In June, the risk level for advanced regenerative medicine using cultured autologous immune cells, including natural killer (NK) cells, was lowered from medium to low. CHA Biotech is developing the autologous NK cell therapy CHANK-101, as well as next-generation cell therapies based on the CHAMS and CHAGE platforms.
Stunning Value Research identified CGB (Cell Gene Bioplatform) at Pangyo 2nd Techno Valley as a key medium- to long-term growth driver.
CGB, which received approval for use in March, has a total floor area of approximately 66,000 square meters and is being equipped with CGT CDMO and current good manufacturing practice (cGMP) production facilities, a biobank, and research facilities.
The key going forward is not the scale of the facilities but the connections among the businesses. The structure links its proprietary pipeline to clinical trials and treatment through its hospital network, while CGB handles production. If Matica Biotechnology in the United States is also integrated, CHA Biotech could establish a global CGT value chain spanning research and development, clinical trials, production, and treatment.
Lee said, “The company’s proprietary research and development pipeline and CGB and CDMO operations handle production, while domestic and overseas hospital infrastructure provides access to clinical trials and treatment.” He added, “Strengthening the connections among clinical trials, production, and treatment could become a differentiating factor for the business.”


[email protected] Kim Kyung-a Reporter